165 related articles for article (PubMed ID: 24046118)
1. Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine.
Schueneman AJ; Sugar EA; Uram J; Bigelow E; Herman JM; Edil BH; Jaffee EM; Zheng L; Laheru DA
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S725-30. PubMed ID: 24046118
[TBL] [Abstract][Full Text] [Related]
2. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.
Lutz E; Yeo CJ; Lillemoe KD; Biedrzycki B; Kobrin B; Herman J; Sugar E; Piantadosi S; Cameron JL; Solt S; Onners B; Tartakovsky I; Choi M; Sharma R; Illei PB; Hruban RH; Abrams RA; Le D; Jaffee E; Laheru D
Ann Surg; 2011 Feb; 253(2):328-35. PubMed ID: 21217520
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.
Zheng L; Ding D; Edil BH; Judkins C; Durham JN; Thomas DL; Bever KM; Mo G; Solt SE; Hoare JA; Bhattacharya R; Zhu Q; Osipov A; Onner B; Purtell KA; Cai H; Parkinson R; Hacker-Prietz A; Herman JM; Le DT; Azad NS; De Jesus-Acosta AMC; Blair AB; Kim V; Soares KC; Manos L; Cameron JL; Makary MA; Weiss MJ; Schulick RD; He J; Wolfgang CL; Thompson ED; Anders RA; Sugar E; Jaffee EM; Laheru DA
Clin Cancer Res; 2021 Mar; 27(5):1278-1286. PubMed ID: 33277370
[TBL] [Abstract][Full Text] [Related]
4. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.
Jaffee EM; Hruban RH; Biedrzycki B; Laheru D; Schepers K; Sauter PR; Goemann M; Coleman J; Grochow L; Donehower RC; Lillemoe KD; O'Reilly S; Abrams RA; Pardoll DM; Cameron JL; Yeo CJ
J Clin Oncol; 2001 Jan; 19(1):145-56. PubMed ID: 11134207
[TBL] [Abstract][Full Text] [Related]
5. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
[TBL] [Abstract][Full Text] [Related]
7. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
Le DT; Lutz E; Uram JN; Sugar EA; Onners B; Solt S; Zheng L; Diaz LA; Donehower RC; Jaffee EM; Laheru DA
J Immunother; 2013 Sep; 36(7):382-9. PubMed ID: 23924790
[TBL] [Abstract][Full Text] [Related]
9. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
[TBL] [Abstract][Full Text] [Related]
10. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.
Lutz ER; Wu AA; Bigelow E; Sharma R; Mo G; Soares K; Solt S; Dorman A; Wamwea A; Yager A; Laheru D; Wolfgang CL; Wang J; Hruban RH; Anders RA; Jaffee EM; Zheng L
Cancer Immunol Res; 2014 Jul; 2(7):616-31. PubMed ID: 24942756
[TBL] [Abstract][Full Text] [Related]
12. A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.
Zheng L; Edil BH; Soares KC; El-Shami K; Uram JN; Judkins C; Zhang Z; Onners B; Laheru D; Pardoll D; Jaffee EM; Schulick RD
Ann Surg Oncol; 2014 Nov; 21(12):3931-7. PubMed ID: 24943235
[TBL] [Abstract][Full Text] [Related]
13. Role of adjuvant therapy in the management of pancreatic cancer.
Laheru D; Yeo CJ
Adv Surg; 2005; 39():223-44. PubMed ID: 16250554
[No Abstract] [Full Text] [Related]
14. Impact of Immunotherapy after Resection of Pancreatic Cancer.
Tran TB; Maker VK; Maker AV
J Am Coll Surg; 2019 Jul; 229(1):19-27.e1. PubMed ID: 30742911
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.
Laheru D; Lutz E; Burke J; Biedrzycki B; Solt S; Onners B; Tartakovsky I; Nemunaitis J; Le D; Sugar E; Hege K; Jaffee E
Clin Cancer Res; 2008 Mar; 14(5):1455-63. PubMed ID: 18316569
[TBL] [Abstract][Full Text] [Related]
16. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
17. Novel pancreatic cancer vaccines could unleash the army within.
Springett GM
Cancer Control; 2014 Jul; 21(3):242-6. PubMed ID: 24955709
[TBL] [Abstract][Full Text] [Related]
18. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC).
Xiang ZJ; Hu T; Wang Y; Wang H; Xu L; Cui N
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510138
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
Dillman RO; Wiemann M; Nayak SK; DeLeon C; Hood K; DePriest C
J Immunother; 2003; 26(4):367-73. PubMed ID: 12843799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
